CEPI represents the first step towards Joseph Stiglitz’s vision, cited by Gubby, of a fund which provides large rewards for cures to common diseases such as malaria, and smaller rewards for rarer diseases or less innovative ‘me‐too’ drugs (Stiglitz, BMJ, 333, 2006, pp. 1279–1280). As a fledgling organization facing a Goliath, it deserves international support in its dual goals of incentivizing innovation and ensuring equitable access to biomedical advances.
Inclusive Biomedical Innovation during the COVID‐19 Pandemic